Clinical Trial Update: Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Mild Alzheimer's Patients. [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing safety and tolerability of repeated subcutaneous injections of CAD106 in patients with Alzheimer's disease has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• CAD106

Snippet

Sponsor: Novartis | Conditions: Alzheimer Disease | Phase 2 | Status: COMPLETED